Business
Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near-Term Milestones
First-in-class catheter-based sensing and ablation technology that targets neural signals that indicate pain or disease and destroys them at the source
About this update from Autonomix Medical, Inc.
[{"type":"text","content":"First-in-class catheter-based sensing and ablation technology that targets neural signals that indicate pain or disease and destroys them at the source Positive 7-day topline results from first five lead-in patients of the ongoing proof-of-concept (PoC) human clinical trial in pain associated with pancreatic cancer 4–6-week follow-up data expected before end of Q3 CY2024 and topline data from the trial expected 1H CY2025 THE WOODLANDS, TX, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today reported financial results for the first quarter fiscal year 2025 ended June 30, 2024 and provided a corporate update. Recent Highlights Appointed proven medical technology leader, Brad Hauser, as President and Chief Executive Officer;Completed licensing transaction with RF Innovations, Inc., a privately held medical technology company, to license the intellectual property to its FDA-cleared ablation technology, the Apex 6 Radiofrequency Generator;Enrolled and treated the first patients that will be formally included in the PoC trial data results and analysis of trial objectives;Announced positive 7-day topline results from the first five lead-in patients in its ongoing PoC human clinical trial: The first five lead-in patients successfully completed protocols with no immediate procedural-related complications or significant adverse events;60% of subjects responded with a mean 6.33 reduction of pain on the VAS pain scale (from baseline of 8.0 to 1.67) at 7-days post-procedure;Pain relief for the above responder group was experienced as quick as 1-day post-procedure; and100% of this responder group had clinically meaningful pain relief at 7-days post-procedure. Received Ethics Committee approval of the protocol amendment for its ongoing PoC human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain; andLaunched “CEO Corner” platform as a communications tool to frequently connect with investors. “We are extremely pleased with the progress and clinical data we have generated to date as it underscores the potential of our technology to significantly benefit patients suffering f...